Spectral AI, Inc.
Spectral AI develops predictive medical diagnostics, with a focus on assessing burn wounds. Its DeepView System combines multispectral imaging with AI software to classify tissue as healing or non-healing and help health care professionals assess wound healing potential. The DeepView AI-Burn software is used with the DeepView SnapShot imaging device. Other programs include the handheld DeepView SnapShot M and software-based 3-D wound measurement technology. Spectral AI’s planned commercial model has two components: software licensing fees, including maintenance, image hosting and algorithm updates, and sales of imaging devices. It also receives funding through government contracts and awards. The company’s corporate headquarters is in Dallas, Texas.
No SEC Form 4 filings for $MDAI in the last 30 days.
See all $MDAI insider activity →Spectral AI reported Q3 GAAP EPS of -$0.11, beating estimates by $0.03, but revenue of $2.86M missed by $2.47M, down 24.5% year-over-year. Shares fell 3.9% after hours.
Spectral AI (MDAI) submitted an NTAP application for its DeepView System, seeking additional Medicare payments. The CMS decision is expected in August 2027, with potential payments starting in October 2027 if approved. The DeepView System, FDA-authorized in May 2026, assesses burn-wound healing potential. The company anticipates reimbursement could offset hospital costs and reduce adoption barriers, subject to CMS requirements.
Spectral AI (MDAI) filed a CMS NTAP application for its DeepView System, aiming for U.S. reimbursement support. A decision is expected in Aug 2027, with potential payments starting in Oct 2027 if approved, lasting about three years. According to the company, this is an early commercialization step following FDA clearance.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning MDAI (Spectral AI, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent MDAI coverage spans regulation, earnings and technology.
Earnings miss on revenue outweighs a modest EPS beat, likely pressuring the stock lower.
Positive regulatory filing that may boost investor sentiment if CMS approves the NTAP, but approval is not expected until 2027.
If CMS approves the payment add‑on, Spectral AI could see revenue upside from Medicare reimbursements.
If CMS approves the NTAP, Spectral AI could receive additional Medicare payments covering up to ~65% of the technology cost, improving the economics of its DeepView system.
Positive catalyst as the study could broaden FDA clearance and market opportunity.
AlphAI scores every news story that mentions MDAI with an AI model for sentiment and relevance, and aggregates insider trades from Spectral AI, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Spectral AI reported Q3 GAAP EPS of -$0.11, beating estimates by $0.03, but revenue of $2.86M missed by $2.47M, down 24.5% year-over-year. Shares fell 3.9% after hours.
Spectral AI (MDAI) submitted an NTAP application for its DeepView System, seeking additional Medicare payments. The CMS decision is expected in August 2027, with potential payments starting in October 2027 if approved. The DeepView System, FDA-authorized in May 2026, assesses burn-wound healing potential. The company anticipates reimbursement could offset hospital costs and reduce adoption barriers, subject to CMS requirements.
Spectral AI (MDAI) filed a CMS NTAP application for its DeepView System, aiming for U.S. reimbursement support. A decision is expected in Aug 2027, with potential payments starting in Oct 2027 if approved, lasting about three years. According to the company, this is an early commercialization step following FDA clearance.
Spectral AI (Nasdaq: MDAI) submitted a New Technology Add-On Payment (NTAP) application for its DeepView™ System to the CMS. The DeepView System, a non-invasive predictive medical device for burn wound assessment, received FDA De Novo Classification in May 2026. If approved, NTAP could provide additional Medicare payments, offsetting costs for hospitals. CMS is expected to make a decision in August 2027, with potential payments starting in October 2027.
Spectral AI (MDAI) announced the first Site Initiation Visit for a clinical study to expand the use of its DeepView System for burns on the head, hands, and feet. The study, led by Dr. Preetha Muthayya at Pinderfields Hospital, UK, aims to support a label expansion and is expected to complete in 2027. The DeepView System, FDA-cleared for burn assessment, uses AI to predict healing potential.
Spectral AI (MDAI) showcased its FDA-cleared DeepView System for burn wound assessment at a conference. The company expects U.S. commercial sales by year-end 2026. Q2 2026 net loss narrowed to $4.2M, with revenue expected to reach $18.5M for the year. Stock closed at $1.55, down 2.52%.
Spectral AI, Inc. (MDAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Spectral AI Announces 2026 Second Quarter Financial Results Company Continues to Advance Towards First Commercial Sales of the DeepView ® System for Burn Indication Strong Cash Position of $14.0 Million at June 30, 2026 DALLAS, TX – August 11, 2026 – Spectral AI, Inc
Spectral AI, Inc. (MDAI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-99.1 2 ea029741201ex99-1.htm OFFER LETTER, BY AND BETWEEN DARCY BAJKO AND SPECTRAL AI, INC., DATED JULY 7, 2026 Exhibit 99.1 Darcy L. Bajko Cleveland, OH Re: Offer of Employment Dear Darcy, Spectral AI, Inc. (the “ Company ”) is pleased to make an offer of employment as Chief
Spectral AI, Inc. (Nasdaq: MDAI) appointed Darcy Bajko as Chief Commercial Officer effective July 31, 2026, to lead global sales for its FDA De Novo-cleared DeepView System for burn indication. The company said it aims to close its first commercial sales by year end 2026 and target adoption in US burn centers and emergency departments.
Spectral AI (MDAI) shares fell about 12% in Tuesday trading after the company said the U.S. FDA granted De Novo classification for its DeepView System, used in burn care. The company said the approval allows it to begin commercial distribution in the U.S. The stock was about $2.34, down from $2.68 at the prior close.
